Sorafenib is a multikinase inhibitor that inhibits downstream intracellular threonine/serine kinases like RAF/BRAF (rapidly accelerated fibrosarcoma) and tyrosine kinase receptors that are located on the cell surface (such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF)) [54]. This evidence concerns the gene VEGFA and fibrosarcoma.